C-Rad Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

C-Rad heeft een totaal eigen vermogen van SEK310.2M en een totale schuld van SEK0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk SEK450.1M en SEK139.9M. De EBIT C-Rad is SEK66.4M waardoor de rentedekking -13.8 is. Het heeft contanten en kortetermijnbeleggingen van SEK118.7M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

SEK 0

Schuld

Rente dekkingsratio	-13.8x
Contant	SEK 118.70m
Aandelen	SEK 310.20m
Totaal verplichtingen	SEK 139.90m
Totaal activa	SEK 450.10m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( SEK399.4M ) 0R44 } overtreffen de korte termijn passiva ( SEK127.2M ).

Langlopende schulden: De kortetermijnactiva 0R44 ( SEK399.4M ) overtreffen de langetermijnschulden ( SEK12.7M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 0R44 is schuldenvrij.

Schuld verminderen: 0R44 had 5 jaar geleden geen schulden.

Schuldendekking: 0R44 heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: 0R44 heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.

C-Rad Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

C-Rad AB (publ) to Report Q3, 2025 Results on Oct 23, 2025

Independent Director recently bought kr190k worth of stock

New minor risk - Market cap size

Third quarter 2024 earnings released: EPS: kr0.45 (vs kr0.32 in 3Q 2023)

CEO & President recently bought kr85k worth of stock

Second quarter 2024 earnings released: EPS: kr0.31 (vs kr0.16 in 2Q 2023)

Full year 2023 earnings released: EPS: kr1.05 (vs kr0.22 in FY 2022)

C-Rad AB (publ) Appoints Mats Thorén as Board Member

C-Rad AB (publ) to Report Fiscal Year 2023 Results on Apr 23, 2024

Full year 2023 earnings released: EPS: kr1.36 (vs kr0.22 in FY 2022)

C-Rad AB (publ) to Report Q3, 2024 Results on Oct 23, 2024

Third quarter 2023 earnings released

Investor sentiment improves as stock rises 17%

Less than half of directors are independent

C-Rad AB (Publ) Announces Former Employee Appeals Verdict from the Patent and Market Court of Appeal

New major risk - Earnings quality

C-Rad AB (publ) to Demonstrate Enhancements in Surface Guided Solutions for Advanced Radiotherapy Treatments at AAPM

Second quarter 2023 earnings released

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

C-Rad AB (publ) to Report Fiscal Year 2022 Final Results on Apr 06, 2023

C-Rad AB (Publ) Appoints Christoffer Herou as CFO

C-Rad AB (Publ) Announces CEO Changes

C-Rad AB (publ) Announces CFO Changes

C-Rad AB (publ) to Report Q3, 2023 Results on Oct 27, 2023

C-RAD Launches New Updated eDucation Portal as an Online Platform

Second quarter 2022 earnings released

Henrik Bergentoft Resigns as CFO of C-RAD

C-Rad Announces CEO Changes

Insufficient new directors

Insufficient new directors

C-Rad AB (publ) to Report Q3, 2022 Results on Oct 28, 2022

C-Rad Achieves Another Milestone Ensuring the Availability of SGRT, the Standard of Care for Radiotherapy

Third quarter 2021 earnings released

Chief Operating Officer recently sold kr625k worth of stock

Second quarter 2021 earnings released

C-Rad AB (publ) Announces The Patent and Market Court Rejected Former Employee Claim for Compensation

The Patent and Market Court of Appeal Issues Judgement Confirming C-Rad's Entitlement to Beamocular's Invention

Full year 2020 earnings released: EPS kr0.43 (vs kr0.45 loss in FY 2019)

C-RAD and Alliance Radiation Oncology Announce That Alliance Has Become the First Center in the Greater Northshore Area to Integrate C-Rad

C-Rad and With-Global Engages in a Partnership for the South Korean Market

C-RAD Receives Order for Proton Cancer Treatment Centers in the US

Shenzhen Proton Therapy Treatment Center Selects C-Rad Catalyst™ System

C-Rad AB (publ) to Report Q2, 2021 Results on Jul 29, 2021

Shanghai Proton and Heavy Ion Hospital Decides for C-Rad Sigrt Solution

Australian Customers Select C-RAD’s Cutting Edge SIGRT Solution

C-Rad AB Receives SEK 11 Million Order for Cutting Edge SIGRT Solution by DTZ in Berlin

Independent Director recently sold kr672.4k worth of stock

Independent Director recently bought kr1.7m worth of stock

Independent Director recently sold kr3.4m worth of stock

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven